Short description
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Description
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease.
Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013.
BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Carlsbad, California, United States, North America
Founded on
January 1, 1990
Exited on
September 10, 2015
Went public on
September 10, 2015
Stock symbol
BTX
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Judith Segall, Michael D West, Paul Segall
Funding rounds count
1
Portfolio organisations count
No Way, Noaccessforu
Sign in for full access
Exits count
Noaccessforu, Noaccess
Sign in for full access
IPO exits count
1